Arrow and the Hawkesbury Canoe Classic (HCC) fund targeted therapies
The vital work of Arrow / HCC research scientist, Dr Tim Molloy, and projects undertaken by Arrow / HCC PhD scholarship students will continue to improve treatments for bone marrow transplant patients thanks to a $93,000 donation from Arrow’s major supporter, the Hawkesbury Canoe Classic (HCC).
Dr Tim Molloy said: “Having the support of Arrow and the people who take part in the HCC is invaluable to me and my research. We’ve come a long way in the treatment and search for a cure for leukaemia, but we haven’t reached the finish line yet. Since 1994, the year that the Hawkesbury Canoe Classic first started supporting the Arrow, there have been dozens of new targeted therapies that have reached various stages of development for the treatment of not just leukaemia, but a range of different bone marrow related diseases, and these are starting to offer real hope for significantly improving the outcome for a large number of patients.”
Arrow Chairman Mark O’Hara and Vice Chairman Neil Pennock were among the paddlers who took on the 111 km overnight event in October last year. Their 13-hour paddle was captured in a video that will be launched next week to provide a real insight into what the HCC is all about.
And it’s time to get ready for the 2019 Classic which takes place on the 26th & 27th October 2019. As if the Classic is not enough, the HCC are planning to add some exciting new challenges for 2019.